›› 2018, Vol. 38 ›› Issue (4): 374-.doi: 10.3969/j.issn.1674-8115.2018.04.004

• Original article (Basic research) • Previous Articles     Next Articles

Effect of APS-Ⅱ-2 on intra-amniotic lipopolysaccharide-induced alveolarization arrest in bronchopulmonary dysplasia model rats

LI Wen1, TAN Zhen2, LIU Cheng-bo1, WANG Zheng-tao3, ZHANG Yong-jun1   

  1. 1. Department of Neonatology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China; 2. Department of Paediatric Hematology/Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China; 3. Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
  • Online:2018-04-28 Published:2018-05-03
  • Supported by:
    National Natural Science Foundation of China, 81671501;Opening Project of Shanghai Key Laboratory of Compound Chinese Medicines, 17DZ2273300

Abstract: Objective · To investigate the role of APS-Ⅱ-2 (a kind of plant-derived natural drug) on amelioration of chorioamnionitis-induced alveolarization arrest and the underlying mechanism. Methods · Bronchopulmonary dysplasia (BPD) model was constructedintra-amniotic injection of lipopolysaccharide(LPS) in SD rats (E16.5). The SD rats were randomly divided into control group (Saline group)、LPS model group (LPS+Saline group) and APS-Ⅱ-2administration group (LPS+APS-Ⅱ-2 group). Then neonatal rats in LPS+APS-Ⅱ-2 group were given an intraperitoneal injection with APS-Ⅱ-2 (50 mg/kg) for 3 consecutive days after birth, whereas rats in LPS+Saline group and Saline group were administrated with an equal amount of normal saline. To examine pathologic change of pulmonary in neonatal rats, hematoxylin-eosin (H-E) staining was performed at postnatal day1 and 3. Then bone marrow-derived macrophages (BMDMs) SD rats were detectedthe technology of RNA-sequence to research the immunomodulation of APS-Ⅱ-2.Results · APS-Ⅱ-2 administration group had drastically higher terminal air spaces (P0.033 at postnatal day1) and secondary septa counts at postnatalday1 and 3, respectively (P0.002, P0.026) than LPS-induced model group, while mean linear intercept was the opposite situation at postnatal day1and 3, respectively (P0.006, P0.004). The detection of RNA-sequence indicated that APS-Ⅱ-2 suppressed the of inflammatory cytokines such as Tlr3, Tlr7 and Tlr8 in BMDMs. Meanwhile, it also promoted some pleiotropic cytokines with anti-inflammatory effects such as Alox15 and Cd74. Conclusion · Administration of APS-Ⅱ-2 could improve the pathology of BPD, thereby supporting the ethno pharmacological uses of the plant. This effect may be directly causedmodulatory effects of APS-Ⅱ-2 on inflammation.

Key words: bronchopulmonary dysplasia, APS-Ⅱ-2, chorioamnionitis, inflammation

CLC Number: